Background: Semaphorin 3B (SEMA3B) is characterized as a strong suppressing factor of the proliferation of cancerous cells and also by its anti-angiogenic effect. However, the knowledge on the changes in the expression profile of SEMA3B under the influence of cisplatin in endometrial cancer remains fragmented. The aim of this work was to note the changes in expression of SEMA3B when under the influence of cisplatin in the endometrial cancer cell line.
Methods: Ishikawa cell line cells were exposed to three different concentrations of cisplatin: 2.5μM; 5μM; 10μM for 12, 24 and 48 hours and were compared to cells untreated by the drug. Changes in the expression profile of SEMA3B were determined based upon RtqPCR (mRNA) alongside the ELISA assay (protein). The Statistica 13.0 PL program was used for statistical analysis (p<0.05).
Results: Changes on the transcriptome level seem to be more dynamic than on the proteome level. Regardless of the concentration given or the exposition period, the expression of semaphorin 3B was, in fact, higher in cells exposed to cisplatin. Statistically substantial differences (p<0.05) in the expression of SEMA3B mRNA and protein were seen for all incubation periods at the given cisplatin level when compared to the control.
Conclusion: Cisplatin causes a growth in the expression of SEMA3B in an endometrial cancer cell culture, this results in the restoration in the state of cell homeostasis and shows the effectiveness of pharmacotherapy, including a low risk of drug resistance.
[http://dx.doi.org/10.1016/j.cell.2018.12.009] [PMID: 30661757]
[http://dx.doi.org/10.1038/s41389-018-0105-z] [PMID: 30518871]
[http://dx.doi.org/10.2174/1389201020666190911113611] [PMID: 31544715]
[http://dx.doi.org/10.1038/onc.2017.165] [PMID: 28581515]
[http://dx.doi.org/10.3892/or.2016.4901] [PMID: 27349960]
[http://dx.doi.org/10.1097/AOG.0b013e31826bb121] [PMID: 23090535]
[http://dx.doi.org/10.1111/dth.13112] [PMID: 31605567]
[http://dx.doi.org/10.1016/j.yexcr.2009.04.018] [PMID: 19409892]
[http://dx.doi.org/10.2217/pme-2018-0112] [PMID: 31109249]
[http://dx.doi.org/10.1200/JCO.2004.00.7617] [PMID: 16330675]
[http://dx.doi.org/10.18632/oncotarget.16316] [PMID: 28418882]
[http://dx.doi.org/10.1186/s12964-016-0127-0] [PMID: 26759169]
[http://dx.doi.org/10.18632/oncotarget.9028] [PMID: 27127883]
[http://dx.doi.org/10.2174/1389201020666190111163312] [PMID: 30636601]
[http://dx.doi.org/10.1016/j.critrevonc.2019.03.004] [PMID: 31014509]
[http://dx.doi.org/10.1007/s10585-019-09964-3] [PMID: 30915595]
[http://dx.doi.org/10.1016/S1470-2045(17)30777-5] [PMID: 29242041]
[http://dx.doi.org/10.12659/MSM.916762] [PMID: 31217417]
[http://dx.doi.org/10.1111/dth.13129] [PMID: 31631469]